Circ0005199-173aa protein and application thereof in preparation of esophageal cancer diagnosis product

• Main Authors: TAN BINGHUA, WANG KEFENG, LIANG RUIHAO, LI LIN, LEI KAI, WANG MINGHUI, LYU YINGCHENG, HU XUETING, WU DUOGUANG, LIN HUAYUE, WANG WENJIAN
• Format: Patent
• Language: Chinese; English
• Published: 15.07.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; TESTING; VINEGAR; WINE

The invention discloses a circ0005199-173aa protein and an application of the circ0005199-173aa protein in preparation of an esophageal cancer diagnosis product. The research shows that the circ0005199-173aa protein expression level is obviously related to a larger tumor diameter, a higher clinical stage and a shorter five-year total lifetime (OS) of an esophageal cancer patient, and the circ0005199-173aa protein can be used as a biomarker for esophageal cancer clinical treatment prognosis prediction; the circ0005199-173aa protein in esophageal cancer tumor tissues can be detected by virtue of an immunohistochemical staining technology (IHC), so that the clinical treatment prognosis effect of esophageal cancer patients can be judged, and more active treatment and close follow-up visit can be favorably carried out on the patients with poor esophageal cancer prognosis clinically. 本发明公开了circ0005199-173aa蛋白及其在制备食管癌诊断产品中的应用。本发明研究显示circ0005199-173aa蛋白表达水平与食管癌患者更大的肿瘤直径、更高的临床分期和更短的五年总生存期（OS）显着相关，其可作为食管癌临床治疗预后预测的生物标志物